FATE THERAPEUTICS INC (FATE) ROI
- 2019-06-30: ROI -53.39%.
- 2019-03-31: ROI -44.93%.
- 2018-12-31: ROI -37.98%.
- 2018-09-30: ROI -33.41%.
Complete source-backed roi history.
- Available history
- 2012-12-31 to 2019-06-30
- Data captured
Historical ROI
| Date | ROI |
|---|
| 2019-06-30 | -53.39% |
|---|
| 2019-03-31 | -44.93% |
|---|
| 2018-12-31 | -37.98% |
|---|
| 2018-09-30 | -33.41% |
|---|
| 2018-06-30 | -85.45% |
|---|
| 2018-03-31 | -58.83% |
|---|
| 2017-03-31 | -48.53% |
|---|
| 2016-12-31 | -39.91% |
|---|
| 2016-09-30 | -86.74% |
|---|
| 2016-06-30 | -82.61% |
|---|
| 2016-03-31 | -64.69% |
|---|
| 2015-12-31 | -53.29% |
|---|
| 2015-09-30 | -44.88% |
|---|
| 2015-06-30 | -40.27% |
|---|
| 2015-03-31 | -65.45% |
|---|
| 2014-12-31 | -53.98% |
|---|
| 2014-09-30 | -58.26% |
|---|
| 2013-12-31 | -38.46% |
|---|
| 2013-09-30 | 30.09% |
|---|
Annual ROI
| Date | ROI |
|---|
| 2018-12-31 | -37.98% |
|---|
| 2016-12-31 | -39.91% |
|---|
| 2015-12-31 | -53.29% |
|---|
| 2014-12-31 | -53.98% |
|---|
| 2013-12-31 | -38.46% |
|---|
| 2012-12-31 | 28.97% |
|---|
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
|---|
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
|---|